ArticleInfection and drug resistance2020
Characterization of an IMP-4-Producing
Article in Infection and drug resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- Role of Mobilome in Carbapenem Resistance.Antibiotics (Basel, Switzerland) · 2026Review
- Mobile genetic elements encoding antibiotic resistance genes and virulence genes inFrontiers in microbiology · 2025Review
- Enhancement ofFrontiers in microbiology · 2025Article
- Mechanism for transmission and pathogenesis of carbapenem-resistant Enterobacterales harboring the carbapenemase IMP and clinical countermeasures.Microbiology spectrum · 2024Article
- Antimicrobial Peptides: From Design to Clinical Application.Antibiotics (Basel, Switzerland) · 2022Review
- A case report of pyogenic liver abscess caused by hypervirulentThe Journal of international medical research · 2021Article
- Using Whole Genome Sequencing to Trace, Control and Characterize a Hospital Infection of IMP-4-ProducingFrontiers in public health · 2021Article
- First Report ofFrontiers in microbiology · 2021Article
- IncN1 ST7 Epidemic Plasmid Carrying blaIMP-4 in One ST85-TypeInfection and drug resistance · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeImipenemase (IMP), an Ambler class B metallo-β-lactamase, is an important carbapenemase that confers resistance to almost all β-lactams. In this study, we characterized the genomic feature of an IMP-4-producing PATIENTS AND
methods
results
conclusionIn summary, our study reports the first genome sequence of a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.